Clinical trials
Advanced or Metastatic Non-small Cell Lung Cancer clinical trials
Below are recruiting advanced or metastatic non-small cell lung cancer clinical trials, each written for real people, not researchers. We’re tracking 5,671 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06477614RecruitingPhase 1
Personalized vaccine for advanced solid tumors
This trial tests a personalized vaccine made from your own immune cells (dendritic cells) to help your body fight advanced cancer. It is for people whose cancer has not responded to other treatments.
Guanzhou, GuangdongAges 18–80 - NCT06123494RecruitingPhase 3
A trial of SHR-A1811 for HER2-positive gastric cancer
This trial tests a new drug, SHR-A1811, for people with HER2-positive stomach or gastroesophageal junction cancer that has worsened after initial treatment. It aims to see if this drug can help when standard anti-HER2 therapy stops working.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06041503RecruitingPhase 2
Treating rare bladder and testicular cancers with targeted therapy
This trial tests a combination of two drugs (enfortumab vedotin and pembrolizumab) for people with certain rare cancers of the urinary tract or testicles. The goal is to see if these treatments can shrink tumors or stop them from growing.
Bethesda, MarylandAges 18–120 - NCT07423338Recruiting
Monitoring breathing muscles in respiratory failure patients
This study tests a new way to monitor breathing muscles in patients who need extra oxygen or breathing support, like a mask or high-flow oxygen. It may help doctors better understand how to treat respiratory failure.
LondonAges 18 years+ - NCT07428278Recruiting
Resilience-building for advance care planning in cancer
This trial tests a program to help people with advanced cancer and their family caregivers build resilience while planning future medical care. It aims to improve communication and preparedness.
Chicago, IllinoisAges 18–80 - NCT07446452RecruitingPhase 2
Combination treatment for HER2-low advanced breast cancer
This trial tests a combination of two drugs, disitamab vedotin and bevacizumab, for people with a specific type of advanced breast cancer called HER2-low. It is designed for those who have already been treated with a drug called T-DXd and need further options.
Nanjing, JiangsuAges 18–75 - NCT06598930Recruiting
Nurse-led follow-up after mild lung blood clot
This study compares two ways of following up after a non-severe pulmonary embolism: standard medical care alone versus intensive monitoring that includes an advanced practice nurse. The goal is to see if the nurse-led follow-up improves your recovery and quality of life.
DijonAges 18 years+ - NCT07444268RecruitingPhase 1
Study of how DSP-5336 is processed in the body in advanced blood cancer patients
This trial looks at how your body absorbs, breaks down, and gets rid of the study drug DSP-5336 after a single dose. It is for people with advanced blood cancers that have come back or not responded to other treatments.
Chapel Hill, North CarolinaAges 18 years+ - NCT07408310Recruiting
Spiritual care support for advanced cancer patients
This trial tests whether spiritual care from a chaplain helps people with advanced cancer. If you belong to a faith community and haven't seen a healthcare chaplain recently, you may be able to join.
New York, New YorkAges 18 years+ - NCT06858735RecruitingPhase 2
HYPERION CCA: a Phase 2 Trial of Systemic Therapy With or Without Liver-directed Radiation Therapy for Patients With Advanced Intrahepatic Cholangiocarcinoma
Phase 2 trial evaluating systemic therapy ± liver-directed RT for advanced intrahepatic cholangiocarcinoma, with broad eligibility for patients who have received at least 4 cycles of gem/cis/durvalumab.
Houston, TexasAges 18 years+ - NCT05955170RecruitingPhase 2
Tucatinib plus oral chemo and trastuzumab for metastatic HER2+ breast cancer
This Phase 2 trial studies tucatinib combined with oral etoposide and trastuzumab in people with metastatic HER2-positive breast cancer, aiming to slow cancer growth. You may be eligible if you previously had progression on a similar HER2-targeted treatment or cannot take capecitabine for medical reasons.
Clermont-Ferrand, Clermont FerrandAges 18 years+ - NCT07611825RecruitingPhase 2
Gut Bacteria Treatment for Advanced Kidney Cancer Resistant to Immunotherapy
This study tests whether modifying your gut bacteria can help immunotherapy work again in advanced kidney cancer that has stopped responding to initial immune-checkpoint inhibitor treatment. Researchers will give you a special bacterial preparation along with a new immunotherapy drug to see if this combination can slow or shrink your cancer.
Nanjing, JiangsuAges 18–90 - NCT03891706RecruitingPhase 1
Personalized T-cell therapy for advanced solid tumors
This early-phase study tests personalized immune cells (T cells) made from your own tumor and blood to treat advanced solid cancers. It may help your immune system recognize and attack your tumor, especially if standard treatments no longer work.
Guangzhou, GaungdongAges 18–70 - NCT07235176RecruitingPhase 1/Phase 2
QLS1304 plus hormone therapy for ER+ breast cancer
This trial tests a new drug called QLS1304 combined with hormone therapy for people with ER-positive, HER2-negative breast cancer that has spread or come back and no longer responds to hormone therapy alone. The goal is to see if this combination can help shrink tumors or slow the disease.
ShanghaiAges 18 years+ - NCT07382544RecruitingPhase 1
Study of BMS-986504 with olaparib for MTAP-loss cancers
This trial tests a combination of two drugs (BMS-986504 and olaparib) for people with advanced solid tumors that have a specific genetic change called MTAP loss. It aims to see if this combination can help when standard treatments have stopped working or aren't available.
Houston, TexasAges 18 years+ - NCT07377643RecruitingPhase 3
New drug combo for advanced HER2-positive breast cancer
This trial tests a new drug called IBI354 (an antibody-drug conjugate) given with or without pertuzumab, compared to the standard combination of taxane, trastuzumab, and pertuzumab, for people with HER2-positive breast cancer that has spread and who have not had prior treatment for advanced disease.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06561308RecruitingPhase 2
Immunotherapy plus chemo for advanced endometrial cancer
This trial tests a combination of a PD-1 inhibitor (a type of immunotherapy) with chemotherapy given before surgery for advanced endometrial cancer. The goal is to see if this approach helps shrink the tumor and improve outcomes.
Hangzhou, ZhejiangAges 18–75 - NCT04908566RecruitingPhase 2
PD-1 immunotherapy plus chemotherapy before and after gastric surgery
This trial studies whether adding a PD-1 immune therapy to chemotherapy around the time of surgery can improve outcomes for people with locally advanced stomach or stomach–esophagus junction cancer. It aims to better control the cancer before and reduce the chance it comes back after surgery.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT06985355RecruitingPhase 1/Phase 2
Testing MHB046C injection for advanced solid tumors
This trial tests an experimental drug called MHB046C for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it can shrink tumors or slow their growth.
Guangzhou, GuangdongAges 18 years+ - NCT07482592RecruitingPhase 1
Study of TQB3205 for advanced solid tumors
This trial tests an experimental drug called TQB3205 for people with advanced solid tumors that have not responded to other treatments. The study will check if the drug is safe and how it affects the tumors.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06954558RecruitingPhase 1
GK01 for advanced solid tumors that are hard to treat
This trial tests a new drug called GK01 in patients with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective, and may be an option for those who can have a tumor surgically removed.
TianjinAges 18–70 - NCT06904131Recruiting
CAR-T cell therapy for advanced gynecological cancers
This trial tests a new type of immunotherapy called CAR-T cells for advanced ovarian, uterine, or other gynecological cancers that have not responded to standard treatments. The CAR-T cells are specially designed to target proteins (MUC1, MSLN, PD-L1) found on cancer cells.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06598371RecruitingPhase 1/Phase 2
Study of engineered immune cells for advanced solid tumors
This trial tests a new treatment made from your own immune cells (called tumor-infiltrating lymphocytes) that are genetically modified to fight cancer better. It is for people with certain advanced solid tumors that have not responded well to other treatments.
Houston, TexasAges 18 years+ - NCT06950086RecruitingPhase 1/Phase 2
TYK-00540 tablets for advanced solid tumors
This trial tests a new tablet, TYK-00540, alone or with another drug, for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
Shanghai, Shanghai MunicipalityAges 18 years+
Hear when a new Advanced or Metastatic Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced or metastatic non-small cell lung cancer?
- Yes. Clin2 currently lists 5,671 recruiting advanced or metastatic non-small cell lung cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced or metastatic non-small cell lung cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced or metastatic non-small cell lung cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Metastatic Non-squamous Non Small Cell Lung Cancer
- Advanced Non-squamous Non-small-cell Lung Cancer
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer Metastatic
- Non Small Cell Lung Cancer
- Non-squamous Non-small Cell Lung Cancer
- Locally Advanced Non-Small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.